Last reviewed · How we verify
Placebo2
Placebo2 does not have an active pharmacological mechanism; it is designed as a control in clinical trials.
At a glance
| Generic name | Placebo2 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo2 serves as a comparator in clinical studies to help determine the efficacy of active treatments by controlling for psychological effects and other variables.
Approved indications
Common side effects
Key clinical trials
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO (PHASE2)
- Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ (PHASE2)
- A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (PHASE1, PHASE2)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV (PHASE1)
- Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood (PHASE1)
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |